Pfizer Exec: In Silico ADMET May Be Scary, But It s Desperately Needed in Drug Discovery | GenomeWeb

Pharma researchers mistrust in silico models of ADMET, Han van de Waterbeemd, of Pfizer Global research and development, told an audience at Drug Discovery Technology Europe earlier this month.

Experimental ADMET “feels better”, and computational prediction “feels scary,” according to van de Waterbeemd. But combining the two is likely to lead to more efficient and effective toxicity prediction for drugs in humans, and computational ADMET approaches, he went on to say, are much needed.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.